[HTML][HTML] 利妥昔单抗在儿童原发性肾病综合征的应用新进展
李建， 颜嘉葳， 刘运广 - Advances in Clinical Medicine, 2021 - hanspub.org
… Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody that induces B cell lysis and
apoptosis. It can prevent or delay the recurrence of children with primary nephrotic syndrome …
apoptosis. It can prevent or delay the recurrence of children with primary nephrotic syndrome …
利妥昔单抗在特发性膜性肾病中的治疗
邹佩美， 李航， 蔡建芳， 陈振杰， 李超… - … Medical Sciences Journal, 2018 - cmsj.cams.cn
… B cells mediate typical subepithelial immune deposits in … Pharmacokinetics and
pharmacodynamics analyses showed … Titrating rituximab to circulating B cells to optimize …
pharmacodynamics analyses showed … Titrating rituximab to circulating B cells to optimize …
利妥昔单抗群体药代动力学研究进展
李梦雪， 何杰， 余霞霞， 胡琳璘… - 中国临床药理学与治疗 …, 2023 - manu41.magtech.com.cn
… Phase I to III trials of anti-B cell therapy in non-Hodgkin’s … Population pharmacokinetics of
rituximab in pediatric patients with … It is also used for autoimmune diseases such as rheumatoid …
rituximab in pediatric patients with … It is also used for autoimmune diseases such as rheumatoid …
系统性红斑狼疮生物制剂治疗进展
王令彪， 成浩， 李丹， 李斌， 吕玲 - 药学进展, 2018 - pps.cpu.edu.cn
… BAFF 也称B 淋巴细 胞刺激因子(B cell stimulatory factor,BlyS),… 利妥昔单抗利妥昔单抗(rituximab,美罗华
) 是一种抗CD20 嵌合… Safety, pharmacokinetics and pharmacodynamics of AMG 811…
) 是一种抗CD20 嵌合… Safety, pharmacokinetics and pharmacodynamics of AMG 811…
[PDF][PDF] 利妥昔单抗药物个体化治疗的药学进展
张相林 - 药物不良反应杂志, 2021 - cadrj.com
… on the surface of B cells. The clinical therapeutic effect of rituximab is significant, but its
phar⁃ macological mechanism is complex, the pharmacokinetics/pharmacodynamics (PK/PD) …
phar⁃ macological mechanism is complex, the pharmacokinetics/pharmacodynamics (PK/PD) …
[PDF][PDF] Loncastuximab tesirine-lpyl 的临床研究进展
汪璐， 任燕， 丁子文， 张婧妍， 袁宜耘， 王俊龙， 倪娜 - 世界临床药物, 2022 - jwph.com.cn
… 患者,包括非特指型弥漫性大B 细胞淋巴瘤(diffuse large B cell … 物为利妥昔单抗(rituximab),为了
评估利妥昔单 抗联合吉西他滨,… Phase I pharmacokinetic and pharmacodynamic study of SJG-…
评估利妥昔单 抗联合吉西他滨,… Phase I pharmacokinetic and pharmacodynamic study of SJG-…
肝移植临床免疫抑制剂及新药研究进展.
陈泉余， 蒋师放， 夏仁培， 帅领… - … /Qi Guan Yi Zhi, 2020 - search.ebscohost.com
… cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity
… A case of developing progressive multifocal leukoencephalopathy while using rituximab and …
… A case of developing progressive multifocal leukoencephalopathy while using rituximab and …
[HTML][HTML] 生物制剂在儿童结缔组织病相关间质性肺病中的应用研究进展
龚玲， 舒畅 - Advances in Clinical Medicine, 2023 - hanspub.org
… 利妥昔单抗(Rituximab, RTX)是一种针对B淋巴细胞表面CD20抗原的单克隆单抗,最初被成功
地用于成人和儿童B细胞淋巴瘤的静脉治疗[12] ,目前也被认为是CTD-ILD的一种备选治疗方式,…
地用于成人和儿童B细胞淋巴瘤的静脉治疗[12] ,目前也被认为是CTD-ILD的一种备选治疗方式,…
淋巴瘤自体造血干细胞移植的临床实践优化探索与未来展望
金正明 - 中国癌症杂志, 2022 - china-oncology.com
… Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell
… Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-…
… Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-…
[HTML][HTML] 他克莫司较其它免疫抑制剂在儿童难治性肾病综合征中疗效比较
倪艺齐， 刘运广， 颜嘉葳， 张晓旭， 戴晓琳… - Advances in Clinical …, 2023 - hanspub.org
… (CTX) and rituximab (RTX), levamisole (LMS), etc., have been used alone or in combination
with wide differences in specialist diseases of the kidney of children around the world, so the …
with wide differences in specialist diseases of the kidney of children around the world, so the …